Antimicrobial susceptibility and treatment of clinical cases of yersiniosis in Aotearoa | New Zealand

This study demonstrates that currently almost half of yersiniosis cases interviewed receive antimicrobial treatment, with most prescriptions as directed therapy after a diagnosis has been made. This study also confirms the appropriateness of current treatment guidelines for the management of yersiniosis in NZ, and that most primary care practitioners in the study areas follow these recommendations. Phenotypic testing was well correlated with the genomic assessments of antimicrobial resistance (AMR). Both types of analysis indicated a low level of AMR for <i>Yersinia</i> spp. in New Zealand (NZ) compared to data from overseas studies. However, ongoing surveillance given the burden of yersiniosis and high rates of treatment in NZ is paramount to ensuring timely detection of emerging multi-drug resistance and to help devise evidence-informed interventions.